|1.||Naranmandura, Hua: 3 articles (08/2014 - 04/2007)|
|2.||Chung, Seung-Min: 3 articles (09/2011 - 11/2008)|
|3.||Noh, Ji-Yoon: 3 articles (09/2011 - 11/2008)|
|4.||Lim, Kyung-Min: 3 articles (09/2011 - 11/2008)|
|5.||Chung, Jin-Ho: 3 articles (09/2011 - 11/2008)|
|6.||Gandolfi, A Jay: 3 articles (07/2010 - 10/2006)|
|7.||Zhang, Yan Fang: 2 articles (08/2014 - 06/2013)|
|8.||Le, X Chris: 2 articles (06/2013 - 07/2008)|
|9.||Vélez, D: 2 articles (03/2013 - 06/2011)|
|10.||Devesa, V: 2 articles (03/2013 - 06/2011)|
02/01/2014 - "Methylation-deficient and methylation-proficient cells both acquired a cancer phenotype with MMA(III) exposure at about 20 weeks, based on increased matrix metalloproteinase secretion, colony formation, and invasion. "
01/01/2008 - "Exposure to 10, 50, 75, or 150 ppm MMA(III) caused 5%, 6.7%, 5%, or 0% tumor-bearing animals. "
10/01/2007 - "Our results show urinary DMA(V) and porphyrin profile can be used as an early warning biomarker for chronic MMA(III) exposure before the onset of cancer."
10/01/2006 - "To further substantiate that malignant transformation had occurred, URO-MSC cells were tested after 24 and 52 weeks of exposure to MMA(III) for the ability to form tumors in SCID mice. "
01/01/2012 - "In this study, we profiled IL-8 expression in UROtsa cells exposed to 50 nM MMA(III) for 1 to 5 mo. IL-8 expression was increased mainly in cells after 3 mo MMA(III) exposure, and its production was also found increased in tumors derived from these cells after heterotransplantation in SCID mice. "
|2.||Cardiovascular Diseases (Cardiovascular Disease)
09/01/2009 - "Here we found that MMA(III) and DMA(III) could induce procoagulant activity and apoptosis in platelets, which play key roles in the development of various cardiovascular diseases (CVDs) through excessive thrombus formation. "
11/01/2008 - "To study the role of these metabolites in arsenic-induced cardiovascular diseases, we investigated the effect of monomethylarsonous acid (MMA III), a major trivalent-methylated arsenical, on vasomotor tone of blood vessels. "
11/01/2008 - "Vascular smooth muscle dysfunction induced by monomethylarsonous acid (MMA III): a contributing factor to arsenic-associated cardiovascular diseases."
05/15/2000 - "The results of these studies raise many questions about the potential central role of MMA(III) in the toxicity of inorganic arsenic and to the potential involvement of MMA(III) in the little-understood etiology of hyperkeratosis, hyperpigmentation, and cancer that can result from chronic inorganic arsenic exposure."
04/15/2010 - "Taken together these results support the notion that chronic inflammation is associated within MMA(III)-induced cell transformation and may act as a promoting factor in UROtsa cell transformation."
04/15/2010 - "In this study the chronology of inflammatory cytokines production was profiled in UROtsa cells chronically exposed to the toxic arsenic metabolite, monomethylarsonous acid [50 nM MMA(III)] to know the role of inflammation in cell transformation. "
|5.||Hepatocellular Carcinoma (Hepatoma)
09/01/2005 - "In the present study, we investigated cyto-/genotoxic effects of the arsenic compounds arsenate [As(i)(V)], arsenite [As(i)(III)], monomethylarsonic acid [MMA(V)], monomethylarsonous acid [MMA(III)], dimethylarsinic acid [DMA(V)], dimethylarsinous acid [DMA(III)], and trimethylarsine oxide [TMAO(V)] after an extended exposure time (24 h) and compared the uptake capabilities of fibroblasts (CHO-9 cells: Chinese hamster ovary) used for genotoxicity studies, with those of hepatic cells (Hep G2: hepatoma cell-line). "
|5.||Arsenicals (Arsenic Compounds)
|6.||arsenic acid (arsenate)
|7.||Interleukin-8 (Interleukin 8)
|10.||Cacodylic Acid (Cacodylate)